EACS2023: 883 Long-term durability of rilpivirine-based regimens in a large cohort G. Brucci , I. Panetta , L. Labate , C. Bartalucci , S. Bianchi , F. Centorrino , C. Marelli , S. Mora , M. Giacomini , B. Bruzzone , L. Taramasso , M. Bassetti , A. Di Biagio University of Genoa, Department of Health Sciences (DISSAL), Genoa, Italy, IRCCS Ospedale Policlinico San Martino, Infectious Disease Clinic, Genoa, Italy, University of Genoa, Department of Informatics, Bioengineering, Robotics and System Engineering (DIBRIS), Genoa, Italy, IRCCS Ospedale Policlinico San Martino, Hygiene Unit, Genoa, Italy General data Abstract category: Antiretroviral therapy – observational studies Abstract body Purpose: Purposes of the study were to assess the long-term durability and factors associated with discontinuation of rilpivirine (RPV) single tablet regimens (STRs). Method: A retrospective, observational study was conducted from January 2013 to May 2023. All people with HIV (PWH) aged 18 years or older were included. Virological status, coinfection with HCV and HBV virus and immunological data were retrospectively collected. For those who discontinued RPV-STR, reason and date of discontinuation were collected and, when available, genotypic resistance test (GRT) was collected as well. Results: A total of 650 PWH were included in the study, 420 (64.6%) were male, median age in the cohort was 57 (50-63) years, further characterization of the study population is outlined in table 1.During a median (IQR) follow-up of 359 (264 – 430) weeks, 156 PWH (24.0%) discontinued RPV-STR. Mean duration (±SD) of RPV-STR treatment was 316 (±132) for ART-naïve and 334 (±119) weeks for ART-experienced respectively. Incidence of discontinuation was 3.8 per 100 person-years follow-up. Estimated proportion of discontinuation after 48 and 96 weeks was 3.9% and 7.3%, respectively, without differences between ART-naïve and -experienced PWH (figure 1). Main reasons for discontinuation were: simplification (n = 21, 13.5%), side effects (n = 16, 10.3%), virological failure (VF) (n = 14, 9.0%), drug–drug interactions (n = 13, 8.3%), death or transfer to another center (n = 10, 6.4%), other (n = 2, 1.3%), lost to follow-up and low adherence (n = 1, 0.6%). On multivariable analysis, HBsAg and HCV-Ab positivity were significantly associated with RPV-STR discontinuation with an OR of 3.4 (95%CI 1.6 – 7.1; p = .0010) and 1.6 (95%CI 1.1 – 2.5; p = .0305) respectively. Conclusions: In our cohort virological failure was not significantly correlated with discontinuation of RPV-STR, hence with a thoughtful approach RPV-STR is characterized by long-term efficacy and durability. General conditions 1. I confirm that I previewed this abstract and that all information is correct. I accept that the content of this abstract cannot be modified or corrected after the submission deadline and I am aware that it will be published exactly as submitted.: Yes 2. I confirm that the submission of the abstract constitutes my consent to publication (e.g. conference website, programmes, other promotions, etc.). : Yes 3. I herewith confirm that the contact details saved in this system are those of the corresponding author, who will be notified about the status of the abstract. The corresponding author is responsible for informing the other authors about the status of the abstract.: Yes 4. I agree that all data provided may be used (saved, stored, processed, transmitted and deleted) in compliance with the privacy policy to provide the services described.: Yes 1 1 1 1 2 2 2 3 3 4 2 1,2 1,2 1 2 3 4 169
RkJQdWJsaXNoZXIy Mzc2ODc=